DataMEDS AI, Inc. (MEDS) Stock Price & Analysis
DataMEDS AI, Inc. (MEDS) closed at USD 2.23 on Friday, October 23, 2026, down 3.04% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.3; the Oct 23, 2026 session ranged USD 2.19–2.36 on volume of 346,779 shares. Market capitalization is $10.07M, with a 52-week range of USD 0.82–46.5 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MEDS.md
Key facts (MEDS)
- Last four reported quarters (through Jun 30, 2026): revenue $8.0M, net income -$88.3M (-1100.3% margin) (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -96.1% vs S&P 500 +13.4%; 5Y -98.8% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MEDS)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | — | $18.1M | $23.3M | $8.0M |
| Gross profit | — | $1.8M | -$6.4M | — |
| Operating income | -$2.9M | -$6.1M | -$93.7M | -$70.3M |
| Net income | -$2.9M | -$6.9M | -$101M | -$88.3M |
| EPS (diluted) | -$3.00 | -$7.50 | -$71.50 | — |
| Gross margin | — | 9.7% | -27.5% | — |
| Operating margin | — | -33.9% | -401.7% | -875.7% |
| Net margin | — | -37.8% | -433.9% | -1100.3% |
| Revenue growth | — | — | +28.7% | — |
| Cash + short-term investments | $1K | $1.0M | $43K | — |
| Total debt | — | $23.4M | $23.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MEDS)
P/S 1.3x · EV/Sales 4.9x · Earnings yield -876.60% · Net debt $29.3M · EV $39.4M
Analysts (MEDS)
Consensus None.
Total return (dividends reinvested) (MEDS)
| 1Y (from 2025-10-24) | 5Y (from 2025-02-17) | |
|---|---|---|
| Total return | -96.1% | -98.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -96.2% | -92.9% |
| Volatility (annualized) | 219.5% | 191.3% |
| Max drawdown | -98.5% (Oct 2025→Sep 2026) | -99.6% (Mar 2025→Sep 2026) |
MEDS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Pharmacy Retail Sales | $1.6M | 89.4% | +1945.3% |
| Third Party Logistics Services | $122,728 | 6.9% | -25.4% |
| Product | $66,765 | 3.8% | -99.1% |
| Total revenue | $1.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MEDS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Pharmacy | “Pharmacy recognizes product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, when we transfer promised” |
| Partner | Wellgistics | “May 11, 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad” |
| Partner | Strategix Global | “May 11, 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad” |
| Partner | Amazon (AMZN) | “joint venture of Amazon, Berkshire Hathaway, and JPMorgan Chase) over recent years.” |
| Partner | UPS (UPS) | “partners (i.e., Lyft and Roadie) for prescription delivery; and shipping carriers (i.e., USPS, UPS, FedEx), rising fuel costs will lead” |
| Partner | FedEx (FDX) | “partners (i.e., Lyft and Roadie) for prescription delivery; and shipping carriers (i.e., USPS, UPS, FedEx), rising fuel costs will lead” |
| Partner | Cencora (COR) | “Health's distribution agreement with AmerisourceBergen is subject to early termination in certain circumstances and, upon the expiration” |
| Partner | Wellgistics Health | “acquisition transactions and potential partnerships may also cause us to significantly increase Wellgistics Health's interest expense,” |
| Partner | Datavault AI Inc. (DVLT) | “November 24, 2025, the Company entered into a License Agreement with Datavault AI Inc., pursuant to which the Company obtained a non-transferable” |
| Partner | Nomad Capital | “May 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad Capital” |
Quoted from the company's 10-K filed Mar 20, 2026.
MEDS customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Aug 17, 2026. The company does not name it.
MEDS company outlook (results filed Aug 18, 2026)
- “The Company is expecting to launch the Health Lives Here (HLH) consumer app together with National Football League Alumni Health (NFLAH) in September 2026, targeting patients on or contemplating taking GLP-1 agonist medications in rural communities through their local independent pharmacies.”
Quoted word-for-word from the SEC 8-K results press release.
MEDS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:39 UTC)
| Price | USD 2.23 |
|---|---|
| Change | ▼ 3.04% (down) |
| Previous Close | USD 2.3 |
| Open | USD 2.33 |
| Day Range | USD 2.19 – 2.36 |
| 52-Week Range | USD 0.82 – 46.5 |
| Volume | 346,779 shares |
| Market Cap | $10.07M |
| Exchange | NCM |
Technical Analysis (MEDS)
Nexqual's technical model rates MEDS "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.75 (neutral) |
| vs SMA50 | Below (USD 2.4) |
| MACD | -0.09 (negative) |
Analyst Ratings (MEDS)
Wall Street analysts rate MEDS "None", per Nexqual as of October 24, 2026 at 12:39 UTC.
| Consensus Rating | None |
|---|
Earnings (MEDS)
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financials & Fundamentals (MEDS)
| Total Revenue | $8.02M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -77.20% |
| Gross Margin | -90.64% |
| Operating Margin | -412.68% |
| Profit Margin | +0.00% |
| Current Ratio | 0.14 |
| Total Cash | $2.46M |
| Total Debt | $32.62M |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financial Health Score (MEDS)
Nexqual rates DataMEDS AI, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:39 UTC.
| Growth | Critical — Revenue -77% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2M cash and investments vs $32M debt (Jun 2026, SEC) |
| Cash Flow | Weak — Operating cash flow -$11M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (MEDS)
| Insider Ownership | +44.47% |
|---|---|
| Institutional Ownership | +1.35% |
| Shares Outstanding | 4.52M |
| Float | 1.71M |
| Short % of Float | +15.14% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Leadership (MEDS)
DataMEDS AI, Inc. is led by Prashant Patel M.Sc., R.Ph., Interim Co-CEO, President & Director, per Nexqual as of October 24, 2026 at 12:39 UTC.
| Interim Co-CEO, President & Director | Prashant Patel M.Sc., R.Ph. |
|---|---|
| Chief Technology Officer | Brett Thompson |
Major Backers & Investors (MEDS)
Notable institutional backers of DataMEDS AI, Inc. include Jane Street Group, LLC, Fidelity, according to Nexqual as of October 24, 2026 at 12:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 0.45% |
| Fidelity | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.39% |
| Geode Capital | 0.28% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
From DataMEDS AI, Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)
Key Strengths & Strategy (as disclosed to the SEC)
- The value of the combined Wellgistics Pharmacy and DelivMeds model is to the opportunity to centrally perform the general and specialty services on behalf of our network of independent pharmacies, leveraging proprietary technology solutions thereby reducing network pharmacy administrative burden and associated costs.
- In the near future, we expect that our model will generate recurring SaaS transaction fees for use of our technology to transfer prescriptions into the network.
- We anticipate that DelivMeds will serve as the middleware technology arm to our integrated healthcare ecosystem. hub and clinical services include: aim to provide value to all stakeholders along the continuum of healthcare delivery in what is known as its 5P-Model: Patients, Providers, Pharmacies, Payors or PBMs and Pharmaceutical Manufacturing Companies.
- Our focus on "specialty-lite" and general maintenance conditions will enable us to develop strong relationships with clinical experts and thought leaders in key therapeutic categories.
Partnerships
- Wellgistics Pharmacy continues to see an uptick in utilization, as more patients elect to pay out of pocket due to our low-cost model, which Wellgistics Pharmacy believes is an opportunity to gain market share with small- to medium-size employer groups in a partnership model with other consumer driven healthcare companies.
- May 11, 2023, we entered into a Membership Interest Purchase Agreement with Wellgistics LLC and its owners, Strategix Global LLC, Nomad Capital LLC, Jouska Holdings LLC, and Brian Norton (the "Wellgistics MIPA"), whereby we agreed to acquire all of the issued outstanding membership interests of Wellgistics LLC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AHG | Akso Health Group | USD 1.3 | ▲ 6.56% |
| HSIC | Henry Schein, Inc. | USD 84.96 | ▼ 1.21% |
| CAH | Cardinal Health, Inc. | USD 249.57 | ▼ 2.37% |
| COR | Cencora, Inc. | USD 331 | ▼ 2.21% |
| MCK | McKesson Corporation | USD 1,000.77 | ▼ 1.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt